Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 0.3997 USD -0.08%
Market Cap: $134.5m

Net Margin

-331.3%
Current
Improving
by 152%
vs 3-y average of -483.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-331.3%
=
Net Income
$-108.9m
/
Revenue
$32.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-331.3%
=
Net Income
$-108.9m
/
Revenue
$32.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Sangamo Therapeutics Inc
NASDAQ:SGMO
128.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
166.3B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 15 072 companies
10th percentile
-331.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Sangamo Therapeutics Inc
Glance View

Market Cap
134.5m USD
Industry
Biotechnology

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-331.3%
=
Net Income
$-108.9m
/
Revenue
$32.9m
What is Sangamo Therapeutics Inc's current Net Margin?

The current Net Margin for Sangamo Therapeutics Inc is -331.3%, which is above its 3-year median of -483.3%.

How has Net Margin changed over time?

Over the last 3 years, Sangamo Therapeutics Inc’s Net Margin has decreased from -158.7% to -331.3%. During this period, it reached a low of -2 331.6% on Jun 30, 2024 and a high of -52.8% on Mar 31, 2023.

Back to Top